Nitric oxide in preterm babies

Report by Richard Nicholl, Consultant Neonatologist, Northwick Park Hospital

A 25 week gestation male infant, birth weight 520 g, is transferred ex utero to your neonatal unit for intensive care. On day 19 he remains ventilator dependent and is hypoxic on 60–95% oxygen. The oxygenation index (OI; a measure of respiratory failure) is 18. Chest x ray shows clear lung fields. Echocardiography by a senior paediatric cardiologist shows evidence of pulmonary hypertension. In view of these findings it is felt that a pulmonary vasodilator may help. You discuss entering the INNOVO trial (a multicentre...
randomised controlled trial of addition of inhaled nitric oxide (iNO) to babies with severe respiratory failure (with the parents, who agree; the baby is entered into the control (no addition of iNO) arm. In spite of this, parents ask for “everything” (including iNO) to be tried. Reluctantly you agree and iNO is administered as per the trial protocol (you inform the trial coordinators). The baby does not improve, and dies 24 hours later. Was it reasonable to administer iNO to this baby?

**Structured clinical question**

In ventilated preterm babies with pulmonary hypertension and hypoxia [patient], does addition of inhaled nitric oxide [intervention] reduce mortality [outcome]? 

**Search strategy and outcome**

Using Cochrane Library: 1 relevant. Using PubMed—“nitric oxide” AND “premature” AND “randomised clinical trial”: 5 smaller studies showed short term physiological changes; e.g. Subhedar et al: transient fall in OI with 5 ppm iNO; Skimming et al: equal increases in oxygen tension after 15 min of either 5 or 20 ppm iNO.

The possible longer term side effects of iNO are not known. In spite of this, iNO is being routinely used in many UK neonatal units, without the safeguards implicit in participation in a clinical trial (Safeguarding informed parental involvement in clinical research involving newborn babies and infants. A Position Statement. Royal College of Paediatrics and Child Health, December 1999). (See also Cochrane Library Reviewers’ conclusions—which do not contain the two largest studies above, at time of writing, as they are too recent).

**CLINICAL BOTTOM LINE**

- Preterm infants should not be treated with inhaled nitric oxide outside prospective, randomised controlled trials.
- Long term follow up of these babies is needed.

**Partial plasma exchange transfusion in polycythaemic neonates**

**Report by Tammy Rothenberg, Department of Gastroenterology, Great Ormond Street Hospital**

You are a neonatal junior doctor looking after the special care nursery. You process a capillary blood sample taken on the morning blood round by someone who has now gone home, and find the haematocrit to be high at 69%. You go back to the baby and find the child to be term, of low birth weight, and admitted to the special care nursery because of low Apgars the previous day. He has not been feeding too well, but the neonatal nurses are not otherwise concerned. He is normal on examination, and his venous haematocrit comes back to the baby and find the haematocrit to be high at 69%. You go back to the baby and find the child to be term, of low birth weight, and admitted to the special care nursery because of low Apgars the previous day. He has not been feeding too well, but the neonatal nurses are not otherwise concerned. He is normal on examination, and his venous haematocrit comes back at 68%. Does this baby need a partial plasma exchange transfusion (PPET)?

**Structured clinical question**

In an asymptomatic neonate with an incidental finding of raised venous haematocrit [patient], does treatment with a partial plasma exchange transfusion [intervention] reduce adverse neurological outcome [outcome]?

**Search strategy and outcome**

Using the Cochrane Controlled Trials Register—“Polycythemia”. Verified using Medline—“polycythemia”, “neonate”, AND “RCT filter”. Six papers identified, of which one irrelevant and one of insufficient quality. See table 2.

**Commentary**

The research papers all use hyperviscosity rather than polycythaemia as the basis for their studies. The test for this is
not routinely available, and so in the clinical setting, polycythaemia is used as a marker for hyperviscosity. Hypermobility is the increased internal friction of blood. It varies according to the flow rate; it is in the capillaries, where the flow rate is slow, that the hyperviscosity is thought to contribute to reduced tissue perfusion. Red cell concentration (haematocrit) contributes significantly to viscosity; Bada et al found a consistent correlation between the two \( r = 0.5 \), \( p < 0.001 \).

Neonatal polycythaemia is associated with adverse neurological outcome. All papers in the table included a control group of non-polycythaemic or non-hyperviscous infants. The group of infants in the Black et al study showed a significant overall risk of mild developmental delay; this risk was greater than the modest treatment effect, compared with infants controlled for gestational age, birth weight, but not for perinatal risk factors (see table 2A).

The Bada et al study matched the control group for gestational age, birth weight, and perinatal risk factors (see table 2A).

Regression analysis was performed to determine the effects of these risk factors on outcome. The risk of adverse neurological outcome was more strongly predicted by perinatal risk factors than the presence of hyperviscosity.

It is notable that there was no abnormal neurology in the infants studied at eight months follow up by van der Elst et al, which may be a result of the type of patients included, the small numbers of patients, or the relatively short follow up period. The subjects of the Black et al study included some who were neurologically normal at 1 year, but had developed signs by 2 years of age. However, the relatively low follow up rate (65%) makes the findings tentative at best. Similarly, although the Goldberg et al study has 80% follow up of the 20 patients, only 6/10 of the observation group were studied, in contrast to 10/10 of the treatment group.

It is important to assess whether these patients are comparable to the clinical scenario. Only the van der Elst patients were selected on clinical grounds (“appearing polycythaemic”), the other patients being selected by a screening process. The other factor that makes the van der Elst et al group of patients comparable in particular to this scenario is that the infants included those who had “minor signs”, defined as lethargy, irritability, peripheral cyanosis, vomiting, and poor feeding.

### CLINICAL BOTTOM LINE

- Polycythaemia is a risk factor for later neurological abnormality.
- Partial plasma exchange transfusion has no clear long term benefit in asymptomatic polycythaemia or hyperviscosity, though evidence either way is weak and inconsistent.

---

**Table 2**

<table>
<thead>
<tr>
<th>Citation</th>
<th>Study group</th>
<th>Study type (level of evidence)</th>
<th>Outcome</th>
<th>Key results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bada et al (1992)</td>
<td>28 neonates screening cord blood haematocrit, and found to have both arterial haematocrit &gt;63% with hyperviscosity, and asymptomatic Randomised to PPET or symptomatic care</td>
<td>RCT (level 1b)</td>
<td>Mental development index/IQ</td>
<td>Mean score in treated group 85 v observed 88, difference =-3 (95% CI -19 to +13) Higher borderline retardation rate in treated group 66% v 45%, ARR = 0.21 (95% CI -0.21 to 0.63)</td>
<td>Mean 27.5 mth follow up, assessors blind to neonatal course 71% follow up rate</td>
</tr>
<tr>
<td>Black et al (1985)</td>
<td>93 neonates selected by: admission to nursery at 4–6 h of age, screened by heel prick testing, and found to have both venous polycythaemia (HCT &gt;65%) and hyperviscosity, includes asymptomatic and asymptomatic Randomised to PPET or symptomatic care</td>
<td>RCT (level 1b)</td>
<td>Mental delay rate</td>
<td>Reduced by PPET (18% v 13%), “not significant” (numbers not given)</td>
<td>2 years follow up 65% follow up rate Includes 2 deaths in observed group, one of head trauma and one of hepatitis</td>
</tr>
<tr>
<td>Goldberg et al (1982)</td>
<td>20 neonates, selected by: screening heel prick on all babies, result &gt;68%, and hyperviscous on venous blood, excludes neurologically symptomatic Randomised to PPET or symptomatic care</td>
<td>RCT (level 1b)</td>
<td>Bayley mental development index</td>
<td>Mean difference 2.6 (95% CI -16 to 21) (control score 112)</td>
<td>8 months 80%</td>
</tr>
<tr>
<td>van der Elst et al (1980)</td>
<td>49 neonates selected by: appearance of polycythaemia, central haematocrit &gt;65%, and no symptoms, or mildly symptomatic* Randomised to PPET or symptomatic care</td>
<td>RCT (level 1b)</td>
<td>Developmental score</td>
<td>“No difference”</td>
<td>8 months follow up</td>
</tr>
</tbody>
</table>

**Table 2A**

<table>
<thead>
<tr>
<th>2 year follow up</th>
<th>All hyperviscous infants</th>
<th>Control</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental delay</td>
<td>16%</td>
<td>10%</td>
<td>NS</td>
</tr>
<tr>
<td>Motor delay</td>
<td>27%</td>
<td>2%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Neurological diagnosis</td>
<td>40%</td>
<td>9%</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Phenytoin in traumatic brain injury

Report by Elizabeth A Hunt, PICU Fellow at Johns Hopkins Hospital in Baltimore

A 12 year old boy is admitted to the paediatric intensive care unit after a motor vehicle collision, where he sustained a severe closed head injury. He lost consciousness at the scene and was intubated in the emergency department for a Glasgow Coma Score of 8 and no gag reflex. The boy has no history of seizure activity in the past or at the scene. Your local "Traumatic Brain Injury Protocol" recommends that he receive phenytoin for seizure prophylaxis. You have recently cared for a child who nearly died from phenytoin hypersensitivity syndrome and would like to know if there is a good indication for the drug.

Structured clinical question

In a child with a traumatic brain injury [patient] does phenytoin prophylaxis [intervention] prevent subsequent seizures and/or improve neurological outcome [outcome]?  

Search strategy and outcome

Secondary sources—none since 1972.

Systematic reviews—two, performed by same authors: Cochrane Library (Issue 3, 2001) and Evidence-Based Medicine (v3, 1998; initially published in J Neurol Neurosurg Psychiatry, 1998); reviewed use of "anti-epileptic drugs", not just phenytoin.

Primary research—PubMed query using MeSH subject headings: “Craniocerebral Trauma” AND “Epilepsy, Post-Traumatic” AND “phenytoin” and filter “therapy”.

Search results—52 articles; after “therapy” filter: 4 relevant (1 not placebo controlled, blinded or readily available, therefore not included here, but is included in systematic reviews). See table 3.

Commentary

In addition to determining the potential efficacy of phenytoin as prevention for post-traumatic epilepsy, there are other important outcomes to bear in mind. Although anti-epileptics appear to decrease the rate of early seizures, this has not been shown to result in a lower rate of post-traumatic epilepsy, mortality, or improved cognitive outcome. 1 In addition, multiple studies have shown that continued use of phenytoin in this population is associated with “negative effects on cognitive performance.”

One must also consider that phenytoin is not a benign drug. Although studies have not revealed a high rate of side effects

<table>
<thead>
<tr>
<th>Citation</th>
<th>Study group</th>
<th>Study type (level of evidence)</th>
<th>Outcome</th>
<th>Key results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schierhout et al (2001)</td>
<td>6 controlled trials, 1218 randomised patients, includes studies with both adults and children, some studies used other antiepileptics than phenytoin</td>
<td>Systematic review (level 1a)</td>
<td>Early seizures (in 1st 7 days post-injury) Late seizures (after 1st 7 days post-injury) Mortality Neurologic disability, (Glasgow Outcome Score)</td>
<td>RR for early seizure prevention 0.34 (CI 0.21–0.54), NNT=10; No mortality, RR=1.15 (CI 0.89–1.51); No 9 in death and neurologic disability RR= 0.96 (CI 0.72–1.26); No 9 in late seizures Pooled RR = 1.28 (CI 0.90–1.81)</td>
<td>Early seizure prevention values represent 4 studies with phenytoin and 2 with other agents Studies very heterogeneous in relation to late seizure outcome</td>
</tr>
<tr>
<td>McQueen et al (1983)</td>
<td>164 patients ages 5 to 65 with serious head injuries (pts with seizures 1st wk post injury excluded)</td>
<td>Double blind RCT (level 1b)</td>
<td>Late seizures, overall mortality, skin rashes</td>
<td>No significant differences Late seizure ARR = −0.77% (CI −9.59 to +8.04) Mortality ARR = −3.45% (CI −9.56 to +2.66) Rash ARR = −4.7% (CI −10.32 to +0.91)</td>
<td>Loss to follow up at 2 years 1.2% (5% if include deaths) Authors’ note: based on low incidence of events, future trials will have to be ∼5x larger than theirs to detect an effect</td>
</tr>
<tr>
<td>Young et al (1983)</td>
<td>41 head injured children; (total study 244 pts, adult data published separately with similar results)</td>
<td>Double blind RCT (level 2b)</td>
<td>[Early seizures; data not published in this study, was collected for total study] Late seizures Overall mortality</td>
<td>No significant differences Late seizure ARR = −5.75% (CI −23.16 to +11.66) Mortality = 4.55% (CI −14.88 to +23.88)</td>
<td>Loss to follow up at 2 years 26% for overall study For children (1 withdrawn, 4 deaths in first wk not included in analysis of final 41 pts), otherwise no loss to follow up</td>
</tr>
<tr>
<td>Temkin et al (1990)</td>
<td>404 patients with serious head trauma, 16 years of age and older</td>
<td>Double blind RCT (level 1b) for early seizure outcome, but for late seizure outcome large loss to follow up in both groups in 2 years, thus level 2b</td>
<td>Early seizures (in 1st wk post-injury) Late seizures (from day 8 to the end of the year), Overall mortality, skin rashes</td>
<td>3.6% in treatment arm, 14.2% placebo, RR=0.27 (CI 0.12–0.62) No significant difference; 21.5% treatment, 15.7% placebo RR=1.2 (CI 0.71–2.02) No significant difference Mortality ARR = −2.64% (CI −10.74 to +5.27) Rash ARR = −3.3% (CI −9.27 to +2.58)</td>
<td>24% loss to follow up at 24 months (22.5% in treatment group, 25% in placebo group)</td>
</tr>
</tbody>
</table>
in patients treated with phenytoin for one week post-injury, physicians must still be aware of the potential for not only serious but potentially fatal reactions to the drug. A search of the literature for adverse reactions to prophylactic phenytoin in head injured patients yielded case reports of intravenous site reactions, exfoliative dermatitis, granulocytopenia, and transient hemiparesis. In other patient populations, phenytoin has been associated with permanent B cell immunodeficiency and fatal phenytoin hypersensitivity syndrome. There have also been multiple publications which show that total phenytoin concentrations can be normal in a trauma patient, yet be associated with high free, unbound concentrations because of low albumin. This may be associated with a higher rate of side effects at normal “therapeutic” concentrations.

Recently, a consensus guideline was published stating that “the routine use of seizure prophylaxis later than 1 week following head injury is not recommended.” The guideline recommends using a risk–benefit analysis to decide whether phenytoin or carbamazepine should be considered for high risk patients in the first week post-injury.

**CLINICAL BOTTOM LINE**

- In the first seven days after serious head injury, phenytoin does prevent seizures in some patients (NNT = 10) but has not been shown to decrease mortality or post-traumatic epilepsy. For high risk patients, a physician must weigh the potential risks and benefits before making a decision.
- If phenytoin is used in trauma patients, measure free, “unbound” phenytoin concentrations to avoid toxicity.
- There is currently no indication for prophylactic phenytoin beyond the first week post head injury.